Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 2/20 | 0.76 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.52 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19036323 | 1.00 | GPX4 (0.76) | GPX4TXNRD1GPR52TSHRCASP1 | |
| SCHEMBL19036381 | 0.94 | GPX4 (0.68) | GPX4TXNRD1GPR52TSHRCASP1 | |
| SCHEMBL19036272 | 0.86 | GPX4 (1.00) | GPX4TXNRD1GPR52 | |
| SCHEMBL19036258 | 0.86 | GPX4 (1.00) | GPX4TXNRD1GPR52 | |
| SCHEMBL19042014 | 0.86 | GPX4 (1.00) | GPX4TXNRD1GPR52 | |
| SCHEMBL19036298 | 0.86 | GPX4 (1.00) | GPX4TXNRD1GPR52 | |
| SCHEMBL19036316 | 0.85 | GPX4 (0.76) | GPX4TXNRD1GPR52MAPTPOLB | |
| SCHEMBL19036321 | 0.84 | GPX4 (0.75) | GPX4TXNRD1GPR52CASP1POLB | |
| SCHEMBL19041944 | 0.84 | GPX4 (0.75) | GPX4TXNRD1GPR52CASP1POLB | |
| SCHEMBL19036305 | 0.82 | GPX4 (0.71) | GPX4TXNRD1GPR52MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238631-B2 | Sesquiterpene derivatives and their use in inflammation or cancer treatment | ACADEMIA SINICA (TW) | 2019-03-26 | — | — | US | disclosed |
| US-20170182001-A1 | NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION OR CANCER TREATMENT | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182001-A1 | NOVEL SESQUITERPENE DERIVATIVES AND THEIR USE IN INFLAMMATION OR CANCER TREATMENT | GSTK1, MIF, GSTA1 | GPX4 242/4885TXNRD1 312/4885GPR52 661/4885 |
| US-10238631-B2 | Sesquiterpene derivatives and their use in inflammation or cancer treatment | GSTK1, GSTA1, GTPBP10 | GPX4 227/4885TXNRD1 449/4885GPR52 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.